Moreover, certain antibodies, including Trastuzumab (HER2/Neu), Zalutumumab (EGFR), and Alemtuzumab (CD52) also eliminate tumor cells by means of neutrophil-dependent ADCC. The gene discussed is ERBB2; the disease is neoplasm.